TY - JOUR
T1 - Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia
AU - Harvey, Philip D.
AU - Meltzer, Herbert
AU - Simpson, George M.
AU - Potkin, Steven G.
AU - Loebel, Antony
AU - Siu, Cynthia
AU - Romano, Steven J.
PY - 2004/2/1
Y1 - 2004/2/1
N2 - Objective: To assess changes in cognitive function in stable outpatients with schizophrenia switched to ziprasidone from conventional antipsychotics (n=108), olanzapine (n=104), or risperidone (n=58) because of suboptimal efficacy or poor tolerability. Methods: In three separate 6-week trials, patients received ziprasidone 40 mg b.i.d. for 2 days, followed by 20-80 mg b.i.d. for the next 40 days. Before switching, and at endpoint, patients were evaluated with tests of working and secondary verbal memory, vigilance, visuomotor speed, verbal fluency, and executive functioning. Principal components factor analysis was performed to test for clustering of cognitive variables. Results: Significant improvements were seen at endpoint in secondary verbal memory (in all three groups), vigilance (in patients switched from conventional antipsychotics or risperidone), executive function (in patients switched from conventional antipsychotics or risperidone), and verbal fluency. Factor analysis on baseline scores suggested reduction of the cognitive variables to three factors: verbal skills, attention and short-term memory, and executive functioning. Analysis of z-transformed mean change in factor scores showed significant improvement in verbal skills and global score following the switch from conventional antipsychotics, olanzapine, or risperidone. Conclusions: Patients requiring a change in antipsychotic therapy may exhibit cognitive improvement following a switch to ziprasidone.
AB - Objective: To assess changes in cognitive function in stable outpatients with schizophrenia switched to ziprasidone from conventional antipsychotics (n=108), olanzapine (n=104), or risperidone (n=58) because of suboptimal efficacy or poor tolerability. Methods: In three separate 6-week trials, patients received ziprasidone 40 mg b.i.d. for 2 days, followed by 20-80 mg b.i.d. for the next 40 days. Before switching, and at endpoint, patients were evaluated with tests of working and secondary verbal memory, vigilance, visuomotor speed, verbal fluency, and executive functioning. Principal components factor analysis was performed to test for clustering of cognitive variables. Results: Significant improvements were seen at endpoint in secondary verbal memory (in all three groups), vigilance (in patients switched from conventional antipsychotics or risperidone), executive function (in patients switched from conventional antipsychotics or risperidone), and verbal fluency. Factor analysis on baseline scores suggested reduction of the cognitive variables to three factors: verbal skills, attention and short-term memory, and executive functioning. Analysis of z-transformed mean change in factor scores showed significant improvement in verbal skills and global score following the switch from conventional antipsychotics, olanzapine, or risperidone. Conclusions: Patients requiring a change in antipsychotic therapy may exhibit cognitive improvement following a switch to ziprasidone.
KW - Attention
KW - Atypical antipsychotics
KW - Cognition
KW - Executive functioning
KW - Schizophrenia
KW - Verbal fluency
KW - Vigilance
KW - Ziprasidone
UR - http://www.scopus.com/inward/record.url?scp=0346786359&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346786359&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2003.07.009
DO - 10.1016/j.schres.2003.07.009
M3 - Article
C2 - 15061242
AN - SCOPUS:0346786359
SN - 0920-9964
VL - 66
SP - 101
EP - 113
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 2-3
ER -